An Observational Study of Pegasys in Dual- or Triple-Therapy in Patients With Chronic Hepatitis C

A Roche Project in Cooperation With the Bng (Association of German Resident Gastroenterologists) for Quality Assurance in the Dual- or Triple-therapy of Chronic Hepatitis C With Peg-(40kd)-Interferon Alfa 2a (Pegasys) at Hepatology Centers

This multicenter, observational study will assess the efficacy and the safety of Pegasys (peginterferon alfa 2a) in dual- or triple therapy in patients with chronic hepatitis C. Patients will receive Pegasys and/or ribavirin and/or a protease inhibitor according to local guidelines. Data will be collected for 96 weeks.

Inclusion Criteria:

• Adult patients, >/= 18 years of age
• Diagnosis of chronic hepatitis C
• Patients receiving treatment with Pegasys and/or Copegus (ribavirin) and/or a protease inhibitor according to local label

Exclusion Criteria:

• Contraindications against Pegasys or Copegus
• Not willing or unable to sign written informed consent form